{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:45:43Z","timestamp":1781135143908,"version":"3.54.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00229","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T04:42:19Z","timestamp":1555044139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Basket Trials for Intractable Cancer"],"prefix":"10.3389","volume":"9","author":[{"given":"Bao-Dong","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Sheng","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-med-062016-050343","article-title":"Basket studies: redefining clinical trials in the era of genome-driven oncology","volume":"69","author":"Tao","year":"2018","journal-title":"Annu Rev Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"djv193","DOI":"10.1093\/jnci\/djv193","article-title":"NCI-MATCH launch highlights new trial design in precision-medicine era","volume":"107","author":"Mcneil","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an Open-Label, Phase IIa Multiple Basket Study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.2217\/fon.14.96","article-title":"Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview","volume":"10","author":"Genestreti","year":"2014","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-007-0573-x","article-title":"Third-line therapy for metastatic colorectal cancer","volume":"61","author":"Gundgaard","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","article-title":"Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative","volume":"51","author":"Bogaerts","year":"2015","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S1470-2045(15)00386-1","article-title":"Rare cancers: a sea of opportunity","volume":"17","author":"Boyd","year":"2016","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2147\/CMAR.S144850","article-title":"Adenosquamous carcinoma of the bile duct: a population-based study","volume":"10","author":"Qin","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.lungcan.2017.12.015","article-title":"Primary pulmonary leiomyosarcoma: a population-based study","volume":"116","author":"Qin","year":"2018","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2018.11.010","article-title":"Clinical, pathological and treatment factors associated with the survival of patients with primary pulmonary salivary gland-type tumors","volume":"126","author":"Qin","year":"2018","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1634\/theoncologist.2017-0199","article-title":"Rare tumor clinic: the University of California San Diego moores cancer center experience with a precision therapy approach","volume":"23","author":"Kato","year":"2018","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2015","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.21037\/hbsn.2018.06.06","article-title":"The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?","volume":"7","author":"Xie","year":"2018","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.10.013","article-title":"Chemotherapy in elderly patients with pancreatic cancer: efficacy, feasibility and future perspectives","volume":"72","author":"Macchini","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2017.12.009","article-title":"Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: from different origin cells?","volume":"116","author":"Zhou","year":"2018","journal-title":"Lung Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1454P","DOI":"10.1093\/annonc\/mdw390.22","article-title":"Impact of sepsis and organ dysfunction on cancer patients' mortality","volume":"27","author":"Pereira","year":"2016","journal-title":"Annal Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/annonc\/mdg302","article-title":"Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction","volume":"14","author":"Fleming","year":"2003","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function","volume":"24","author":"Mita","year":"2006","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.ejca.2010.02.022","article-title":"EORTC elderly task force position paper: approach to the older cancer patient","volume":"46","author":"Pallis","year":"2010","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1016\/j.ejca.2015.08.027","article-title":"The effects of age on health-related quality of life in cancer populations: a pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients","volume":"51","author":"Quinten","year":"2015","journal-title":"Eur J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa010957","article-title":"A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients","volume":"345","author":"Sargent","year":"2001","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1532-5415.2006.00789.x","article-title":"A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy","volume":"54","author":"Hurria","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e000020","DOI":"10.1136\/esmoopen-2015-000020","article-title":"Challenge of cancer in the elderly","volume":"1","author":"Marosi","year":"2016","journal-title":"ESMO Open"},{"key":"B42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.resinv.2018.10.003","article-title":"The clinical features of older patients with lung cancer in comparison with their younger counterparts","volume":"57","author":"Ogino","year":"2018","journal-title":"Respir Investig"},{"key":"B43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1089\/jayao.2017.0007","article-title":"Challenges in the treatment of sarcomas of adolescents and young adults","volume":"6","author":"Rotz","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.soc.2017.05.014","article-title":"Future clinical trials: genetically driven trials","volume":"26","author":"Astsaturov","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"key":"B48","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cpt.814","article-title":"Critical review of umbrella, basket, and platform designs for oncology clinical trials","volume":"102","author":"Simon","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJMe1716821","article-title":"Developing anticancer drugs in orphan molecular entities - A paradigm under construction","volume":"378","author":"Andre","year":"2018","journal-title":"N Engl J Med"},{"key":"B51","article-title":"LBA17-Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372\u2013A-001","author":"Demetri","year":"2018"},{"key":"B52","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","article-title":"Genomics-driven oncology: framework for an emerging paradigm","volume":"31","author":"Garraway","year":"2013","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"LBA100","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA100","article-title":"Routine molecular screening of advanced refractory cancer patients: an analysis of the first 2490 patients of the ProfiLER study","volume":"35","author":"Tredan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-17-0381","article-title":"Molecular screening for cancer treatment optimization (MOSCATO-01) in pediatric patients: a single-institutional prospective molecular stratification trial","volume":"23","author":"Harttrampf","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/annonc\/mdw666","article-title":"Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial","volume":"28","author":"Belin","year":"2017","journal-title":"Ann Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2147\/OTT.S120440","article-title":"BRAF(V600) mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study","volume":"10","author":"Cohn","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, Open-label VE-BASKET Study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"JCO2018789990","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study","volume":"36","author":"Kaley","year":"2018","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-017-0504-6","article-title":"Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations","volume":"35","author":"Hasegawa","year":"2017","journal-title":"Invest New Drugs"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","article-title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases","volume":"14","author":"Heinrich","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.73.0143","article-title":"AKT inhibition in solid tumors with AKT1 mutations","volume":"35","author":"Hyman","year":"2017","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT001","article-title":"Neratinib in HER2- or HER3-mutant solid tumors: SUMMIT,a global, multi-histology, open-label, phase 2 \u201cbasket\u201d study","volume-title":"Presented at Annual Meeting American Association for Cancer Research","author":"Hyman","year":"2017"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1093\/annonc\/mdx294","article-title":"Oncologist use and perception of large panel next-generation tumor sequencing","volume":"28","author":"Schram","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T20:36:26Z","timestamp":1663274186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":75,"alternative-id":["10.3389\/fonc.2019.00229"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00229","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"article-number":"229"}}